All News

Last year, a single health care breach involved 2 million records, but in the first half of 2023, there were 5 health care breaches of at least 3 million records each.

The incidence of 12-month surgical repair failure was 19% among those who received vaginal estrogen, compared with 9% among those who received placebo.

The prospective, open-label, phase 2 SOLAR study enrolled 26 patients with metastatic prostate cancer.

The study assessed MG-AGEs, SRAGE, GLO1, and AGER, 4 biomarkers that are associated with methyglyoxal.

"Despite challenges, ongoing research and advancements in risk stratification, imaging techniques, and targeted therapies are paving the way for personalized and precision medicine approaches in prostate cancer management," writes Michael S. Cookson, MD, MMHC, FACS.

Approximately half of prostate cancer patients with clinically actionable gene variants do not meet the NCCN guideline criteria for genetic testing, according to findings from the PROCLAIM trial.

The new drug application is supported by findings from the phase 3 CERTAIN-1 trial.

“The results of the current study indicate that 100% of the elderly patients who were referred for PSMA PET/CT on the basis of clinical suspicion only were found to have avid disease," said Einat Even-Sapir, MD, PhD.

The FoundationOne CDx test will identify patients who are eligible to receive niraparib plus abiraterone based on the genomic profile of their prostate tumor.

“These findings provide encouraging evidence that immune checkpoint inhibitors can be effective in treating a subset of patients with penile squamous cell carcinoma," said co-first author Amin Nassar, a clinical fellow at Yale School of Medicine.

The approval of the niraparib/abiraterone dual-action tablet for BRCA-positive mCRPC is based on findings from the phase 3 MAGNITUDE study.

The SECURE trial exploring 64Cu/67Cu SAR-bisPSMA in patients with metastatic castration-resistant prostate cancer has advanced to the highest dose level.

A total of 158 patients with NMIBC including tumors with stage carcinoma in situ, Ta, and T1 were enrolled in the prospective trial in mainland China.

The urine-based assay measures the expression of HOXC6 and DLX1 to determine whether a patient may benefit from prostate biopsy.

A recent study suggests that combined use of ultrasound and multiparametric MRI-targeted biopsy with systematic biopsy may be more effective for detecting clinically significant prostate cancers than using systematic biopsies alone

The novel test was developed and validated using the biomarkers Appl1, Sortilin, and Syndecan-1 that were studied by investigators at the University of South Australia.

The studies explored the use of opioids following surgery as well as the risk of incisional hernia.

"In patients with prostate cancer considered for surgery, PSMA-PET can provide information on the risk of recurrence after surgery, before the surgery even happens," says Loïc Djaïleb, MD, PhD.

Doctors and medical practices are mired in administrative tasks.

"The study revealed that the anatomical changes in the male pelvis could potentially favor the upright position for prostate treatments,” says Niek Schreuder.

The mitomycin-containing reverse thermal gel UGN-102 with or without TURBT reduced the risk of recurrence, progression, or death vs TURBT alone in patients with low-grade intermediate-risk non-muscle invasive bladder cancer.

Even in the era of PSMA-PET imaging, whole-body low-dose computed tomography still offers value in the management of patients with prostate cancer, according to a study published in Insights into Imaging.

"Data have shown among surgeons in multiple specialties that a good chunk of people have pain; probably around 60% of people have pain that they associate with operating," says Kristin Chrouser, MD, MPH.

"[Our study] suggests that limiting added sugar intake may help to prevent the formation of kidney stones,” says Shan Yin, MD.

The PRESERVE study of the NanoKnife System for the ablation of prostate tissue is exploring the focal treatment in patients with intermediate-risk prostate cancer.

Patients classified as high-risk by the genomic classifier who underwent radical prostatectomy had a 3-fold higher risk of harboring adverse pathology at the time of surgery compared with those with low-risk.

"A lingering question is whether the act is increasing patient knowledge about their physicians’ receipt of payments from the industry (or whether they care)," writes Robert A. Dowling, MD.

Suzanne Merrill, MD, recaps the BCAN 2023 Think Tank session she co-chaired that covered prehabilitation programs, urinary diversion management, and other focal areas aimed at enhancing the quality of bladder cancer care in the community.